Dear Geneos stakeholders and well-wishers,

You only turn one once! Geneos Therapeutics turned 1 today (Feb 21, 2020) as a standalone company. It was exactly a year ago that we closed our Series A financing and formally spun out from our parent company Inovio Pharmaceuticals. What a year it has been for the Geneos team and we have a lot to celebrate. In this past year, we:

- **Established the Geneos team** by recruiting Joann Peters – VP, Clinical Operations; and Dr. Alfredo Perales-Puchalt – VP, R&D who joined James Barlow – VP, Operations and Business Development and myself on the Geneos leadership team. The team is well supported by our team of expert external consultants and advisors notably Dr. Beth Junker – Manufacturing, CMC; Dr. Ildiko Csiki – Oncology clinical development; and internal R&D and clinical staff.

- **Established our GT-EPIC™ platform** and the personalized product manufacturing process chain – an integrated network of partners and CROs supporting us with NGS, seed manufacturing, GMP product manufacturing, and clinical operations. With the GT-EPIC™ platform, Geneos has achieved an industry leading 6-8 weeks Biopsy-to-Treatment turnaround time for treating patients with their own personal immunotherapy starting with a biopsy sample from their own tumor. This is already about half the time that our cancer neoantigen competitors promise. We aim to reduce it by another 2x once all the steps are integrated under one roof in the future.

- **Filed and opened 3 INDs** and built out our pipeline to cover three solid tumor programs:
  - GT-10: Anaplastic astrocytoma (Compassionate use IND to treat a single patient)
  - GT-20: Newly diagnosed GBM
  - GT-30: Advanced hepatocellular carcinoma

- **Treated our first patient** with their own tumor specific personalized immunotherapy demonstrating safety and feasibility of the GT-EPIC™ platform for cancer treatment.

Looking ahead, I see 2020 as the year of efficient clinical execution. We expect to report clinical safety and neoantigen targeted immune response data on all three clinical programs. The versatile GT-EPIC™ platform we have established sets up the company well to build on its initial success and grow/expand into additional cancer indications and treatment modalities in the personalized medicine space. We look forward to taking these next steps upon securing increased future investment and partnerships. Our vision is to treat cancer one patient at a time with treatments that are specific to and based on each person’s tumor.

In closing, we would not be where we are without the support and shared vision of our investors, partners, advisors, and academic/clinical collaborators in enabling us to make rapid progress on our mission. We are thankful to our network of support.

I am pleased to enclose our updated corporate presentation. More details on the GT-EPIC™ platform and our programs can be found at: [www.geneostx.com](http://www.geneostx.com)

Upwards and onwards to an exciting 2020!

Niranjan Y. Sardesai, Ph.D.
Co-Founder, President & CEO